- Tumor chemopotentiation using isocoumarin derivatives
-
A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.
- -
-
-
- PREPARATION OF ISOCOUMARIN DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF
-
A method of preparing optically active isocoumarin-3-yl-acetic acid derivatives represented by Formula (I): wherein a specific isocoumarin-ketene derivative is subjected to an addition reaction with an optically active alcohol, and then the ester thus obtained is subjected to a hydrolysis reaction. An intermediate for synthesis used therein. A method of preparing isocoumarin-3-yl-acetic acid derivatives represented by Formula (III): wherein a specific isocoumarin derivative is subjected to an addition reaction with carbon monoxide and oxygen in the presence of a transition metal catalyst. An intermediate for synthesis used therein.
- -
-
Page/Page column 23-24
(2010/02/07)
-
- Tumor chemopotentiation using isocoumarin derivatives
-
A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.
- -
-
-
- Synthesis and biological evaluation of cytogenin derivatives
-
To enhance the stability in vivo, new derivatives of cytogenin were synthesized, and their biological activity and stability in mice were estimated. 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid (NM-3) was found to be the most stable among them. It modified collagen-induced arthritis in mice. It also showed potent anti-angiogenic activity in a mouse dorsal air sac assay.
- Matsumoto,Nakashima,Isshiki,Kuboki,Hirano,Kumagai,Yoshioka,Ishizuka,Takeuchi
-
p. 285 - 296
(2007/10/03)
-
- Isocoumarin derivatives and use thereof in drugs
-
PCT No. PCT/JP96/01657 Sec. 371 Date Dec. 17, 1998 Sec. 102(e) Date Dec. 17, 1998 PCT Filed Jun. 17, 1996 PCT Pub. No. WO97/48693 PCT Pub. Date Dec. 24, 1997Compounds of the formula (I) wherein R is a hydrogen atom or a C1-6 alkyl group and n is an integer of 0 or 1, and pharmaceutical preparations thereof are provided. These pharmaceutical preparations are useful for the prevention or treatment of diseases associated with an abnormality in immunological regulatory function or vascularization.
- -
-
-
